Novavax (NASDAQ:NVAX) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Novavax (NASDAQ:NVAX) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06, FiscalAI reports. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The firm had revenue of $56.70 million for the quarter, compared to analyst estimates of $52.51 million. During the same period in the previous year, the firm posted $0.62 EPS. The company’s revenue for the quarter was down 76.2% compared to the same quarter last year.

Here are the key takeaways from Novavax’s conference call:

• Sanofi partnership momentum strengthened: Sanofi is in advanced regulatory discussions for a Phase III COVID-19/flu combination vaccine, which could trigger a $125 million milestone, while a manufacturing tech-transfer milestone could add $75 million by mid-2027 and extend Novavax’s cash runway into 2029.
• 2026 financial outlook improved: Novavax raised its adjusted revenue framework to $235 million-$275 million, citing stronger Matrix-M demand and expected Takeda and Serum Institute royalties and milestones, while lowering combined GAAP R&D and SG&A expense guidance by $10 million at the midpoint.
• Matrix-M partnering activity is broadening: Four of the top 10 global pharmaceutical companies now have licensing or material-transfer agreements, covering more than 30 areas of experimentation across infectious disease and oncology. Novavax also signed an oncology-focused MTA with a leading global pharmaceutical company.
• Pipeline progress remains early-stage: The preventive C. difficile vaccine began GMP manufacturing and pre-IND discussions, with potential clinical entry as early as 2027, while oncology data are encouraging but remain primarily mechanistic or preclinical and partner timelines are uncertain.
• Reported results reflect ongoing losses and potential restructuring charges: Second-quarter revenue fell to $57 million from $239 million a year earlier, largely because 2025 included a $202 million milestone and Takeda amendment benefit; Novavax posted a $53 million net loss and flagged up to a $35 million non-cash fixed-asset write-off in 2027.

Novavax Stock Up 2.7%

NVAX traded up $0.21 during trading on Friday, hitting $7.95. The company’s stock had a trading volume of 5,697,898 shares, compared to its average volume of 3,146,678. Novavax has a twelve month low of $6.20 and a twelve month high of $11.97. The stock’s fifty day moving average price is $8.72 and its 200-day moving average price is $8.97. The firm has a market capitalization of $1.31 billion, a P/E ratio of -5.23 and a beta of 2.46.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a second-quarter adjusted loss of $0.32 per share, better than the expected $0.38 loss, while revenue of $56.7 million exceeded estimates of approximately $52.5 million. NVAX Q2 Earnings & Sales Beat Estimates, 2026 Sales Outlook Raised
• Positive Sentiment: The company raised its full-year 2026 adjusted revenue framework to $235 million-$275 million from $230 million-$270 million and reduced combined GAAP research and development and selling, general and administrative expense guidance by $10 million at the midpoint. Novavax Raises 2026 Outlook After Q2 Beat
• Positive Sentiment: Novavax said completion of its manufacturing technology transfer to Sanofi is expected in mid-2027, potentially triggering a $75 million milestone payment. Sanofi also plans to advance discussions with regulators regarding timing for its Phase 3 COVID-19 and influenza combination-vaccine trial. Novavax Lifts Annual Revenue Forecast
• Neutral Sentiment: Novavax ended June with approximately $724 million in cash, cash equivalents, marketable securities and restricted cash. It also highlighted partner-led Matrix-M projects and plans to move its C. difficile vaccine program into clinical development as early as 2027. Novavax Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Revenue fell approximately 76% from the prior-year quarter to $56.7 million, product sales were only $19 million, and Novavax posted a $53 million net loss versus $107 million of net income a year earlier. The results underscore the company’s dependence on licensing revenue and milestone payments as vaccine demand wanes. Novavax Q2 Revenue Falls 76 Percent

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NVAX. Quarry LP bought a new stake in Novavax in the third quarter valued at $33,000. Danske Bank A S bought a new position in shares of Novavax during the 3rd quarter worth about $64,000. State of Wyoming acquired a new stake in shares of Novavax in the 2nd quarter valued at about $52,000. Scientech Research LLC acquired a new stake in shares of Novavax in the 3rd quarter valued at about $96,000. Finally, Dimensional Fund Advisors LP bought a new stake in Novavax in the 4th quarter valued at about $75,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NVAX shares. Wall Street Zen lowered shares of Novavax from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Weiss Ratings reissued a “sell (d)” rating on shares of Novavax in a research report on Tuesday. B. Riley Financial restated a “buy” rating on shares of Novavax in a report on Thursday, April 9th. BTIG Research restated a “buy” rating and issued a $19.00 price target on shares of Novavax in a research report on Thursday, June 11th. Finally, Zacks Research raised shares of Novavax from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $13.00.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.